> top > docs > PMC:7787218 > spans > 10578-11273 > annotations

PMC:7787218 / 10578-11273 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T41 176-187 Phenotype denotes anaphylaxis http://purl.obolibrary.org/obo/HP_0100845
T42 279-290 Phenotype denotes anaphylaxis http://purl.obolibrary.org/obo/HP_0100845
T43 368-375 Phenotype denotes allergy http://purl.obolibrary.org/obo/HP_0012393
T44 476-492 Phenotype denotes hypersensitivity http://purl.obolibrary.org/obo/HP_0041092

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
180 347-354 Species denotes persons Tax:9606
181 617-627 Species denotes SARS-CoV-2 Tax:2697049
182 368-375 Disease denotes allergy MESH:D004342
183 476-492 Disease denotes hypersensitivity MESH:D004342

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T35 0-147 Sentence denotes We are now entering a critical period during which we will move rapidly through phased vaccination of various priority subgroups of the population.
T36 148-437 Sentence denotes In response to the cases of anaphylaxis associated with the Pfizer–BioNTech vaccine in the United Kingdom and now several cases of anaphylaxis in the United States, the CDC has recommended that only persons with a known allergy to any component of the vaccine be excluded from vaccination.
T37 438-695 Sentence denotes A systematic approach to the existing hypersensitivity cases and any new ones will ensure that our strategy will maintain safety not only for this vaccine but for future mRNA and SARS-CoV-2 vaccines with shared or similar components (Figure 1 and Table 1).6